Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 10
Submit an article Journal homepage
17,544
Views
23
CrossRef citations to date
0
Altmetric
Oncology

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Tom Martina UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
,
Saad Z. Usmanib Levine Cancer Institute-Atrium Health, Charlotte, NC, USA
,
Jordan M. Schecterc Janssen R&D, Raritan, NJ, USA
,
Martin Vogeld Janssen Global Services, LLC, Raritan, NJ, USA
,
Carolyn C. Jacksonc Janssen R&D, Raritan, NJ, USA
,
William Deraedte Janssen R&D, Beerse, BelgiumORCID Iconhttps://orcid.org/0000-0003-1414-2387
ORCID Icon,
Hong Tianc Janssen R&D, Raritan, NJ, USA
,
Tzu-min Yehc Janssen R&D, Raritan, NJ, USA
,
Arnob Banerjeef Janssen R&D, Lower Gwynedd Township, PA, USA
,
Lida Pacaudg Legend Biotech USA, Inc, Piscataway, NJ, USA
,
Ashraf Garrettg Legend Biotech USA, Inc, Piscataway, NJ, USA
,
Anja Haltnerh EVERSANA, Sydney, NS, CanadaORCID Iconhttps://orcid.org/0000-0002-9829-7791
ORCID Icon,
Chris Cameronh EVERSANA, Sydney, NS, CanadaORCID Iconhttps://orcid.org/0000-0003-3613-760X
ORCID Icon,
Suzy Van Sandene Janssen R&D, Beerse, Belgium
,
Joris Dielse Janssen R&D, Beerse, Belgium
,
Satish Vallurid Janssen Global Services, LLC, Raritan, NJ, USA
&
Imtiaz A. Samjooi EVERSANA, Burlington, ON, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1415-8055
ORCID Icon show all
Pages 1779-1788 | Received 06 Jun 2021, Accepted 06 Jul 2021, Published online: 23 Jul 2021

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Sundar Jagannath, Carolyn C. Jackson, Jordan M. Schecter, Nikoletta Lendvai, Huabin Sun, Muhammad Akram, Nitin Patel & Thomas G. Martin. (2024) Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma. Expert Opinion on Biological Therapy 0:0, pages 1-12.
Read now
Irene Strassl & Klaus Podar. (2024) The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma. Expert Opinion on Drug Discovery 19:4, pages 377-391.
Read now
Thomas G Martin, Deepu Madduri, Lida Pacaud & Saad Z Usmani. (2023) Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology 19:34, pages 2297-2311.
Read now
Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Roccia, Carolyn C. Jackson, William Deraedt, Tzu-min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Meaghan Bartlett, Anja Haltner, Suzy Van Sanden, Joris Diels, Satish Valluri & Imtiaz A. Samjoo. (2023) Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion 39:1, pages 81-89.
Read now
Massimo Offidani, Laura Corvatta, Sonia Morè, Maria Valentina Manieri & Attilio Olivieri. (2022) An update on novel multiple myeloma targets. Expert Review of Hematology 15:6, pages 519-537.
Read now

Articles from other publishers (18)

Sueh‐li Lim, Cameron Wellard, Elizabeth Moore, Simon J. Harrison, Quach Hang, Joy Ho, Rajeev Rajagopal & Andrew Spencer. (2023) Real‐world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry . Internal Medicine Journal 54:5, pages 773-778.
Crossref
Jie Xu, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, Jian Hou, Zhu Chen, Wan-Hong Zhao, Ai-Li He, Jian-Qing Mi & Sai-Juan Chen. (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. Journal of Hematology & Oncology 17:1.
Crossref
Jude Franklin, Prateek Pophali, Zachary Jackson, David Wald & David Avigan. 2024. Molecular Hematology. Molecular Hematology 369 396 .
Zainul S. Hasanali, Beatrice Razzo, Sandra P. Susanibar-Adaniya, Alfred L. Garfall, Edward A. Stadtmauer & Adam D. Cohen. (2024) Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America 38:2, pages 383-406.
Crossref
Jiamin Fang & Fuling Zhou. (2023) BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. Annals of Hematology 103:4, pages 1069-1083.
Crossref
Larry D. AndersonJrJr, Binod Dhakal, Tania Jain, Olalekan O. Oluwole, Gunjan L. Shah, Surbhi Sidana, Miguel-Angel Perales & Marcelo C. Pasquini. (2024) Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy 30:1, pages 17-37.
Crossref
Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Yukihiro Miyazaki, Chika Iwamoto, Takashi Saitou, Takeshi Imamura, Masaki Yasukawa & Katsuto Takenaka. (2023) Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE. Blood 142:21, pages 1789-1805.
Crossref
William C Temple, Matthew A Nix, Akul Naik, Adila Izgutdina, Benjamin J Huang, Gianina Wicaksono, Paul Phojanakong, Juan Antonio Camara Serrano, Elizabeth P Young, Emilio Ramos, Fernando Salangsang, Veronica Steri, Simayijiang Xirenayi, Michelle Hermiston, Aaron C Logan, Elliot Stieglitz & Arun P Wiita. (2023) Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. Journal for ImmunoTherapy of Cancer 11:11, pages e006985.
Crossref
Lukas John, Sandra Sauer, Ute Hegenbart, Peter Dreger, Michael Hundemer, Carsten Müller-Tidow, Anita Schmitt, Michael Schmitt, Marc S. Raab & Stefan O. Schönland. (2023) Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy 29:10, pages 609.e1-609.e6.
Crossref
Kelsey Beck, Tyler Sandahl, Sikander Ailawadhi, Nandita Khera & Chelsee Jensen. (2023) Multiple Myeloma: Current Clinical Landscape and Compounding Costs. Current Hematologic Malignancy Reports 18:5, pages 201-215.
Crossref
Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev & Saad Z Usmani. (2023) Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research 12:6.
Crossref
Eden Biltibo & Jesus G. Berdeja. (2023) SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions. Clinical Lymphoma Myeloma and Leukemia 23:5, pages 310-321.
Crossref
Mendel Goldfinger, Nishi Shah & Dennis L. Cooper. (2023) Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma—A Call for Equal Opportunity. JAMA Oncology 9:3, pages 297.
Crossref
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin & Sundar Jagannath. (2023) Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of Clinical Oncology 41:6, pages 1265-1274.
Crossref
Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert & Riley Taiji. (2023) Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. Cancer Medicine.
Crossref
Buthainah Ghanem & Lu Shi. (2022) The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. BioDrugs 36:6, pages 773-780.
Crossref
Endeshaw Chekol Abebe, Mestet Yibeltal Shiferaw, Fitalew Tadele Admasu & Tadesse Asmamaw Dejenie. (2022) Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers in Immunology 13.
Crossref
Ruiting Guo, Wenyi Lu, Yi Zhang, Xinping Cao, Xin Jin & Mingfeng Zhao. (2022) Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting. Frontiers in Immunology 13.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.